Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
28 nov. 2023 08h00 HE
|
Onconova Therapeutics, Inc.
Onconova presenting at NobleCon19 Dec 4-5 in Boca Raton, FL
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
14 nov. 2023 16h05 HE
|
Onconova Therapeutics, Inc.
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
07 nov. 2023 16h05 HE
|
Onconova Therapeutics, Inc.
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL
02 nov. 2023 10h37 HE
|
Onconova Therapeutics, Inc.
Preclinical data indicate that narazaciclib shows monotherapy and combination anti-tumor activity in ibrutinib-sensitive and resistant cells and xenograft models NEWTOWN, Pa., Nov. 02, 2023 (GLOBE...
Onconova Expands Leadership Team with Two Key Appointments
24 oct. 2023 08h00 HE
|
Onconova Therapeutics, Inc.
Onconova Expands Leadership Team: Victor Moyo named Chief Medical Officer, Meena Arora joins as Vice President Global Medical Affairs and R&D
Promising Preclinical Narazaciclib Data Presented at MCL Meeting
19 oct. 2023 08h00 HE
|
Onconova Therapeutics, Inc.
Data for Mantle cell lymphoma (MCL) presented in Ireland on Oct. 7, 2023Additional studies support broad potential, especially in cyclin-dependent cancers NEWTOWN, Pa., Oct. 19, 2023 (GLOBE...
Encouraging Rigosertib Data Presented at EADV as Late Breaker
12 oct. 2023 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Oct. 12, 2023 (GLOBE NEWSWIRE) -- (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on...
Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress
28 sept. 2023 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and...
Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
06 sept. 2023 08h00 HE
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and...
Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results
10 août 2023 16h05 HE
|
Onconova Therapeutics, Inc.
Anticipate topline results from the Phase 1 monotherapy and Phase 1/2 combination study with letrozole in Q4 2023 Plans are underway for a registrational trial with rigosertib in patients with...